FDA’s Psychedelic Drug Rescheduling: A Step Forward with Limits

The U.S. Food and Drug Administration (FDA) has long been criticized for its slow and often arbitrary approval processes, which can delay or deny access to critical medications and medical devices. The agency’s regulatory grip extends even to mundane products, such as its nine-page regulation on the proper classification of "frozen lasagna," which mandates compliance with specific standards under 21 CFR § 139.110 through 21 CFR § 139.155.

Economist Alex Tabarrok of George Mason University has highlighted the deadly consequences of the FDA’s incentive structure. He notes that the agency is more likely to delay the introduction of new drugs because "if it approves a bad drug the victims are identifiable." Conversely, "people die but the bodies are buried in an invisible graveyard" when good drugs are delayed or denied. This systemic flaw has fueled debates over the FDA’s role in public health.

Shifting FDA Priorities Under New Leadership

Historically, Republicans have pushed for streamlined drug approvals, but under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., the FDA’s focus has shifted toward alternative scientific ideas, including bans on certain products. Notably, the agency has recently advised nursing homes against providing harmless foods like Jell-O, while Kennedy himself has expressed concerns about seed oils despite his past admissions of drug use.

However, the Trump administration has adopted a more lenient approach to substances previously subject to prohibition. Recent developments include:

• Tobacco and nicotine products: The FDA is considering approval for certain flavors in vaping and snus products to help adult smokers quit.
• Marijuana: An executive order rescheduling marijuana has been issued, though the fine print suggests limited immediate impact. The move aims to expedite testing of cannabis-related pharmaceuticals.
• Psychedelics: A federal executive order last month removed "federal barriers to psychedelic drugs" as a treatment for serious mental illness. Psychedelics like psilocybin mushrooms and ecstasy are now classified as Schedule III, indicating a low potential for dependency. This rescheduling could fast-track clinical testing, provided the FDA follows through—a prospect that remains uncertain.

Psychedelics Rescheduled: Progress with Caveats

The rescheduling of psychedelics to Schedule III is a positive step, but it falls short of legalization or decriminalization. The administration acknowledges the potential of psychedelics, such as psilocybin and MDMA (ecstasy), in certified treatment plans for mental health conditions. However, real change will require sustained effort beyond executive orders, including rigorous clinical testing and FDA approval—a process notorious for its delays.

The FDA’s new approach to psychedelics represents a shift in federal policy, but the agency’s bureaucratic hurdles remain a significant obstacle. While the rescheduling is encouraging, the path to widespread access to these treatments is still fraught with challenges.